Top

Published in:

01-10-2017 | Original Article

A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors

Authors: Maria Sole Chimenti, Paola Triggianese, Paola Conigliaro, Marco Tonelli, Gianfranco Gigliucci, Lucia Novelli, Miriam Teoli, Roberto Perricone

Published in: Clinical Rheumatology | Issue 10/2017

Abstract

The aim of this study was to evaluate clinical remission and MDA in PsA patients who started TNF-inhibitors (TNFi) treatment with a 2-year follow-up. Concomitant therapies as well as comorbidities were assessed. Level of concordance of clinimetric indices and the potential predictive factors of remission/MDA were also evaluated. Clinical and laboratory evaluations were prospectively performed in PsA patients at baseline (T0) and after 22 (T22), 54 (T54), and 102 (T102) weeks of treatment. Disease activity and disability were assessed using DAS28, CPDAI, DAPSA, MDA, and HAQ-SpA. The Pearson correlation coefficient, univariate, and multivariate binary logistic regression were performed. A total of 221 PsA patients were included. Cardiovascular diseases and metabolic syndrome (MetS) resulted as the most frequent comorbidities. Clinical remission was achieved by over a half of the patients during the follow-up. Use of concomitant therapies, such as csDMARDs and steroids, was significantly reduced during the follow-up. Agreement among indices of treatment targets by k-statistics was excellent for CPDAI and DAPSA and good for MDA and DAS28 or DAPSA. Female sex and MetS resulted as negative prognostic factors of clinical remission and MDA at all the time points. TNFi are highly effective in achieving treatment targets in PsA patients. DAS28, CPDAI, DAPSA, and MDA show a good agreement. Female sex and MetS are associated with a lower probability to achieve remission in PsA patients.

Christophers E (2001) Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 26:314–320CrossRefPubMed

Conigliaro P, Chimenti MS, Triggianese P, Sunzini F, Novelli L, Perricone C, Perricone R (2016) Autoantibodies in inflammatory arthritis. Autoimmun Rev 15:673–683CrossRefPubMed

Kane D, Stafford L, Bresnihan B, FitzGerald O (2003) A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 42:1460–1468CrossRef

Chimenti MS, Triggianese P, Conigliaro P, Santoro M, Lucchetti R, Perricone R (2014) Self-reported adherence to a home-based exercise program among patients affected by psoriatic arthritis with minimal disease activity. Drug Dev Res:S57–S59

Chimenti MS, Ballanti E, Perricone C, Cipriani P, Giacomelli R, Perricone R (2013) Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev 12:599–606CrossRefPubMed

Scrivo R, Conigliaro P, Riccieri V, Di Franco M, Alessandri C, Spadaro A, Perricone R, Valesini G (2015) Distribution of interleukin-10 family cytokines in serum and synovial fluid of patients with inflammatory arthritis reveals different contribution to systemic and joint inflammation. Clin Exp Immunol 179:300–308CrossRefPubMedPubMedCentral

Coates LC, Kavanaugh A, Mease PJ et al (2016 May) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68(5):1060–1071PubMed

Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P et al (2014) Targeting spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis:736–716

Coates l, Helliwell P. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010;62:965–969

10.

Kavanaugh A, Fransen J (2006) Defining remission in psoriatic arthritis. Clin Exp Rheumatol 24:83–87

11.

Lubrano E, Perrotta FM, Kavanaugh A (2015) Clin Exp Rheumatol 33:S51–S54PubMed

12.

Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) CASPAR study group: classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673CrossRefPubMed

13.

Castrejón I, Ortiz AM, Toledano E, Castañeda S, García-Vadillo A, Patiño E, González-Alvaro I (2010) Estimated cutoff points for the 28-joint disease activity score based on C-reactive protein in a longitudinal register of early arthritis. J Rheumatol 37:1439–1443CrossRefPubMed

14.

Mumtaz A, Gallagher P, Kirby B et al (2011) Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 70:272–277CrossRefPubMed

15.

Helliwell PS, Fitzgerald O, Fransen J et al (2013) The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 72:986–989CrossRefPubMed

16.

Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64:Suppl 2:ii49–2:ii54

17.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed

18.

Temizkan S, Balaforlou B, Ozderya A, Avci M, Aydin K, Karaman S, Sargin M (2016) Effects of thyrotrophin, thyroid hormones, and thyroid antibodies on metabolic parameters in a euthyroid population with obesity. Clin Endocrinol. doi:10.1111/cen.13095

19.

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645CrossRefPubMed

20.

Moll JM, Wright V (1973) Psoriatic arthritis. Seminars arthritis Rheum 3:55–78CrossRef

21.

Esposito M, Giunta A, Mazzotta A, Zangrilli A, Babino G, Bavetta M et al (2012) Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology 225:312–319CrossRefPubMed

22.

Love TJ, Zhu Y, Zhang Y, Wall-Burns L, Ogdie A, Gelfand JM, Choi HK (2012) Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 71:1273–1277CrossRefPubMedPubMedCentral

23.

Maillefert JF, Combe B, Goupille P, Cantagrel A, Dougados M (2004) The 5-yr HAQ-disability is related to the first year’s changes in the narrowing, rather than erosion score in patients with recent-onset rheumatoid arthritis. Rheumatology (Oxford) 43:79–84

24.

Hotamisligil GS (2006) Nature 444:860–867CrossRefPubMed

25.

Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH (2011) Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken) 63:195–202CrossRef

26.

Eder L, Jayakar J, Pollock R, Pellett F, Thavaneswaran A, Chandran V, Rosen CF, Gladman DD (2013) Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis 72:1956–1961CrossRefPubMed

27.

Chimenti MS, Triggianese P, Conigliaro P, Candi E, Melino G, Perricone R (2015) The interplay between inflammation and metabolism in rheumatoid arthritis. Cell Death Dis 6:e1887CrossRefPubMedPubMedCentral

28.

Haroon M, Gallagher P, Heffernan E, FitzGerald O (2014) High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol 41:1357–1365CrossRefPubMed

29.

Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH et al (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 68:1387–1394CrossRefPubMed

30.

Chimenti MS, Graceffa D, Perricone R (2011) Anti-TNFα discontinuation in rheumatoid and psoriatic arthritis: is it possible after disease remission? Autoimmun Rev 10:636–640CrossRefPubMed

31.

Chimenti MS, Teoli M, Saraceno R, Dattola A, Ventura A, Chiricozzi A et al (2013) Golimumab in patients affected by moderate to severe psoriatic arthritis: an open-label study in thirty-two patients previously treated with other biologics. Dermatology 227:305–310CrossRefPubMed

32.

Bergamini A, Chimenti MS, Baffari E, Guarino MD, Gigliucci G, Perricone C, Perricone R (2014) Downregulation of immunoglobulin-like transcript-4 (ILT4) in patients with psoriatic arthritis. PLoS One 9:e92018CrossRefPubMedPubMedCentral

33.

Conigliaro P, Triggianese P, Perricone C, Chimenti MS, Di Muzio G, Ballanti E et al (2014) Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment. Clin Exp Immunol 177:234–43.35CrossRefPubMedPubMedCentral

34.

Chimenti MS, Esposito M, Giunta A, Graceffa D, Babino G, Teoli M et al (2013 Jul-Sep) Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients’ clinical characteristics leading to disease relapse. Int J Immunopathol Pharmacol 26(3):833–838CrossRefPubMed

35.

Lorenzin M, Ortolan A, de Hooge M, Frallonardo P, Piccoli A, Cozzi F et al (2015 Sep 17) Lengthening the time intervals between doses of biological agents in psoriatic arthritis patients: a single-center retrospective study. Int J Immunopathol Pharmacol

36.

Van den Bosch F, Kavanaugh A, Kron M, Kupper H, Mease PJ (2015) Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations. J Rheumatol 42:952–959CrossRefPubMed

37.

Ranganath VK, Yoon J, Khanna D, Park GS, Furst DE, Elashoff DA et al (2007) Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort. Ann Rheum Dis 66:1633–1640CrossRefPubMedPubMedCentral

38.

Tillet W, Jadon D, Shaddick G, Cavill C, Korendowych E, de Vries CS, McHugh N (2013) Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. Ann Rheum Dis 72:1358–1361CrossRef

39.

Højgaard P, Glintborg B, Hetland ML, Hansen TH, Lage-Hansen PR, Petersen MH et al (2015) Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Ann Rheum Dis 74:2130–2136CrossRefPubMed

40.

Theander E, Husmark T, Alenius GM, Larsson PT, Teleman A, Geijer M, Lindqvist UR (2014) Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish early psoriatic arthritis register (SwePsA). Ann Rheum Dis 73:407–413CrossRefPubMed

41.

Costa L, Caso F, Ramonda R, Del Puente A, Cantarini L, Darda MA et al (2015) Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res 61:147–153CrossRefPubMed

42.

Abou-Raya A, Abou-Raya S (2006) Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 5:331–337CrossRefPubMed

43.

Choi KM, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG et al (2007) Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract 75:235–240CrossRefPubMed

44.

Akahane M, Watanabe M, Inoue N, Miyahara Y, Arakawa Y, Inoue Y, Katsumata Y, Hidaka Y, Iwatani Y (2016 May) Association of the polymorphisms of chemokine genes (IL8, RANTES, MIG, IP10, MCP1 and IL16) with the pathogenesis of autoimmune thyroid diseases. Autoimmunity 31:1–8

45.

Triggianese P, Perricone C, Conigliaro P, Chimenti MS, Perricone R, De Carolis C (2016) Peripheral blood natural killer cells and mild thyroid abnormalities in women with reproductive failure. Int J Immunopathol Pharmacol 29:65–75CrossRefPubMed

46.

Acay A, Ulu MS, Ahsen A, Eroglu S, Ozuguz U, Yuksel S, Acarturk G (2014) Assessment of thyroid disorders and autoimmunity in patients with rheumatic diseases. Endocr Metab Immune Disord Drug Targets 14:182–186CrossRefPubMed

47.

Marin J, Acosta Felquer ML, Ferreyra Garrot L, Ruta S, Rosa J, Soriano ER (2016 May) Patients with psoriatic arthritis fulfilling the minimal disease activity criteria do not have swollen and tender joints, but have active skin. J Rheumatol 43(5):907–910CrossRefPubMed

Title: A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors
Authors: Maria Sole Chimenti
Paola Triggianese
Paola Conigliaro
Marco Tonelli
Gianfranco Gigliucci
Lucia Novelli
Miriam Teoli
Roberto Perricone
Publication date: 01-10-2017
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 10/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-017-3769-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2017

Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series

Upregulation of CD16− monocyte subsets in systemic lupus erythematous patients

Diffusion tensor imaging of mild-moderate carpal tunnel syndrome: correlation with nerve conduction study and clinical tests

Management of chikungunya arthritis

Comparison between different disease activity scores in rheumatoid arthritis: an Egyptian multicenter study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page